Literature DB >> 11593420

BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents.

P B Mullan1, J E Quinn, P M Gilmore, S McWilliams, H Andrews, C Gervin, N McCabe, S McKenna, P White, Y H Song, S Maheswaran, E Liu, D A Haber, P G Johnston, D P Harkin.   

Abstract

BRCA1 is a tumour suppressor gene implicated in the predisposition to early onset breast and ovarian cancer. We have generated cell lines with inducible expression of BRCA1 to evaluate its role in mediating the cellular response to various chemotherapeutic drugs commonly used in the treatment of breast and ovarian cancer. Induction of BRCA1 in the presence of Taxol and Vincristine resulted in a dramatic increase in cell death; an effect that was preceded by an acute arrest at the G2/M phase of the cell cycle and which correlated with BRCA1 mediated induction of GADD45. A proportion of the arrested cells were blocked in mitosis suggesting activation of both a G2 and a mitotic spindle checkpoint. In contrast, no specific interaction was observed between BRCA1 induction and treatment of cells with a range of DNA damaging agents including Cisplatin and Adriamycin. Inducible expression of GADD45 in the presence of Taxol induced both G2 and mitotic arrest in these cells consistent with a role for GADD45 in contributing to these effects. Our results support a role for both BRCA1 and GADD45 in selectively regulating a G2/M checkpoint in response to antimicrotubule agents and raise the possibility that their expression levels in cells may contribute to the toxicity observed with these compounds.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11593420     DOI: 10.1038/sj.onc.1204712

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  33 in total

Review 1.  Fine tuning chemotherapy to match BRCA1 status.

Authors:  Melissa Price; Alvaro N A Monteiro
Journal:  Biochem Pharmacol       Date:  2010-05-25       Impact factor: 5.858

2.  Germline BRCA mutation does not prevent response to taxane-based therapy for the treatment of castration-resistant prostate cancer.

Authors:  David J Gallagher; Angel M Cronin; Matthew I Milowsky; Michael J Morris; Jasmine Bhatia; Peter T Scardino; James A Eastham; Kenneth Offit; Mark E Robson
Journal:  BJU Int       Date:  2011-07-14       Impact factor: 5.588

Review 3.  Impact of biomarkers on non-small cell lung cancer treatment.

Authors:  Luca Toschi; Federico Cappuzzo
Journal:  Target Oncol       Date:  2010-05-05       Impact factor: 4.493

Review 4.  Parameters for individualizing systemic therapy in non-small cell lung cancer.

Authors:  Shirish M Gadgeel; Michele L Cote; Ann G Schwartz; Larry H Matherly; Antoinette Wozniak; Gerold Bepler
Journal:  Drug Resist Updat       Date:  2010-11-03       Impact factor: 18.500

Review 5.  Differential chemotherapeutic sensitivity for breast tumors with "BRCAness": a review.

Authors:  Pavani Chalasani; Robert Livingston
Journal:  Oncologist       Date:  2013-07-23

6.  Analysis of resistance-associated gene expression in docetaxel-resistant prostate cancer cells.

Authors:  Sangchul Lee; Kwangtaek Kim; Jin-Nyoung Ho; Hyunjin Jin; Seok-Soo Byun; Eunsik Lee
Journal:  Oncol Lett       Date:  2017-07-08       Impact factor: 2.967

Review 7.  Can the status of the breast and ovarian cancer susceptibility gene 1 product (BRCA1) predict response to taxane-based cancer therapy?

Authors:  J Thomas De Ligio; Aneliya Velkova; Diego A R Zorio; Alvaro N A Monteiro
Journal:  Anticancer Agents Med Chem       Date:  2009-06       Impact factor: 2.505

8.  BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells.

Authors:  P Tassone; P Tagliaferri; A Perricelli; S Blotta; B Quaresima; M L Martelli; A Goel; V Barbieri; F Costanzo; C R Boland; S Venuta
Journal:  Br J Cancer       Date:  2003-04-22       Impact factor: 7.640

9.  DNA double strand break repair and its association with inherited predispositions to breast cancer.

Authors:  Rodney J Scott
Journal:  Hered Cancer Clin Pract       Date:  2004-02-15       Impact factor: 2.857

10.  MYC prevents apoptosis and enhances endoreduplication induced by paclitaxel.

Authors:  Giuliana Gatti; Giovanna Maresca; Manuela Natoli; Fulvio Florenzano; Angelo Nicolin; Armando Felsani; Igea D'Agnano
Journal:  PLoS One       Date:  2009-05-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.